2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
10/02/18Exicure Presents First Data Demonstrating Both Oral Delivery and Liver Delivery of Spherical Nucleic Acid Constructs in Animal Models
-- Two posters presented at the 14th Annual Meeting of the Oligonucleotide Therapeutics Society in Seattle, Washington -- -- Bio-distribution after oral delivery in mice shows efficacy of Exicure’s technology in a mouse model of inflammatory bowel disease -- -- Pre-clinical data presented by Regulus Therapeutics show Exicure’s technology improves exposure and targets gene modulation in the liver -- SKOKIE, Ill.--(BUSINE... 
Printer Friendly Version
10/01/18Data on Exicure’s TLR9 Agonist Spherical Nucleic Acid (SNA™) Construct Presented at the 4th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
Exicure technology shows effective antitumor activity in mouse tumor models SKOKIE, Ill.--(BUSINESS WIRE)--Oct. 1, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, presented data in a poster session on Sunday, September 30 at the 4th CRI-CIMT-EATI-AACR International Immunotherapy Conference: Translating Science into Survival in N... 
Printer Friendly Version
09/28/18Exicure, Inc. to Present at Upcoming Investor Conference and Participate in Oncology Roundtable
SKOKIE, Ill.--(BUSINESS WIRE)--Sep. 28, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Ladenburg Thalmann 2018 Healthcare Conference and Leerink Partners Roundtable Series: Rare Disease & Oncology. Detai... 
Printer Friendly Version
09/20/18Exicure Announces Positive Phase 1 Results for its Lead Immuno-Oncology Asset
-- First in human results demonstrate potent immune system activation with no serious adverse events or dose limiting toxicity -- SKOKIE, Ill.--(BUSINESS WIRE)--Sep. 20, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, announced today Phase 1 results for AST-008, an SNA consisting of toll-like receptor 9 (TLR9) agonists designed for ... 
Printer Friendly Version
08/22/18Exicure, Inc. Announces Expected Closing of Approximately $22 Million Private Placement Offering
SKOKIE, Ill.--(BUSINESS WIRE)--Aug. 22, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, announced today it expects to close a private placement offering of its common stock at a per share price of $4.50 and aggregate gross proceeds of approximately $22 million before fees and expenses. The private placement is expected to close on or about... 
Printer Friendly Version
08/06/18Exicure, Inc. Provides Update on Corporate Progress and Second Quarter 2018 Financial Results
SKOKIE, Ill.--(BUSINESS WIRE)--Aug. 6, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today reported financial results for the second quarter ended June 30, 2018, and provided an update on corporate progress. “With the addition of a new COO and the topical dosing of XCUR17 in patients with mild to moderate psoriasis, Exicur... 
Printer Friendly Version
06/15/18Exicure, Inc. to Present at the 2018 JMP Securities Life Sciences Conference on June 21st at 11:00 a.m. EDT
SKOKIE, Ill.--(BUSINESS WIRE)--Jun. 15, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the JMP Securities Life Sciences Conference on Thursday, June 21st, 2018 at 11:00 a.m. EDT in New York City at The St. Regis New Yo... 
Printer Friendly Version
06/14/18Exicure to Present Data at the Cure Spinal Muscular Atrophy Annual Conference in Dallas
Exicure’s three-dimensional spherical nucleic acid containing the nusinersen sequence prolongs survival and reduces toxicity compared to nusinersen in a spinal muscular atrophy mouse model SKOKIE, Ill.--(BUSINESS WIRE)--Jun. 14, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, announced today that Exicure and its collaborators at... 
Printer Friendly Version
06/04/18Exicure, Inc. to Present at Jefferies 2018 Healthcare Conference on June 8th at 2:30 p.m. EDT
SKOKIE, Ill.--(BUSINESS WIRE)--Jun. 4, 2018-- Exicure, Inc. (OTCQB:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, announced today that Dr. David Giljohann, Chief Executive Officer of Exicure, will present at the Jefferies 2018 Healthcare Conference on Friday, June 8, 2018 at 2:30 p.m. EDT in New York City at the Grand Hyatt New York. ... 
Printer Friendly Version
05/23/18Exicure, Inc. To Begin Trading on United States OTCQB® Under the Symbol “XCUR”
SKOKIE, Ill.--(BUSINESS WIRE)--May 23, 2018-- Exicure, Inc. (OTC:XCUR), the pioneer in the development and application of three-dimensional Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, is pleased to announce the commencement of the public trading of its common stock. The Company will trade under the ticker “XCUR” effective as of market open on Thursday May 24th, 2018. The Company expects to be quoted on the ... 
Printer Friendly Version
05/15/18Exicure, Inc. Reports First Quarter 2018 Financial Results and Reviews Corporate Progress
Reports progress in immuno-oncology and neurology programsMay 15, 2018 04:15 PM Eastern Daylight TimeSKOKIE, Ill--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today reported financial results for the first quarter ended March 31, 2018, and provided an update on corporate progress."Exicure continues to drive forward our SNA technology through ongoing clinical development. In the fo... 
Printer Friendly Version
04/30/18Exicure Announces Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
Chicago, Illinois – April 30th, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, today announced results from the Phase 1b clinical trial of its compound, AST-005, designed to reduce the expression of tumor necrosis factor (TNF).  In 2016, Exicure entered into a research collaboration, option and license agreement with Purdue Pharma L.P.  As part of Exicure's collaboration with... 
Printer Friendly Version
04/24/18Exicure Announces Chief Executive Officer, Dr. David Giljohann, Named to Endpoints News’ “Under-40s” Biopharma Executives List
SKOKIE, Ill. – April 24, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that the Company's Chief Executive Officer, David Giljohann, Ph.D., has been recognized by Endpoints News as an outstanding up-and-coming biopharma professional under the age of 40.   Dr. Giljohann was Exicure's founding scientist in 2011. He has served as Chief Executive Officer since No... 
Printer Friendly Version
04/20/18Exicure Expands Leadership Team with Appointment of TLR9 Oncology Expert Matthias Schroff as Chief Operating Officer
CHICAGO, IL – April 20, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional spherical nucleic acid (SNA™) constructs, today announced the appointment of Matthias Schroff, Ph.D., to Chief Operating Officer. Dr. Schroff is a biotechnology industry veteran who brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TL... 
Printer Friendly Version
04/16/18Exicure to Present Data at the American Association for Cancer Research (AACR) 2018 Annual Meeting
SKOKIE, Ill. – April 16, 2018 – Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, announced today that it will present preclinical data in a poster session at the American Association for Cancer Research (AACR) 2018 Annual Meeting in Chicago, Illinois from April 14-18, 2018. The poster titled "TLR9 agonist SNA-induced innate and adaptive immune responses in tumor microenvironment enhance checkpoi... 
Printer Friendly Version
03/09/18Exicure, Inc. Reports Full Year 2017 Financial Results and Corporate Progress
Launched Phase 1 clinical trial of AST-008, a TLR9 agonist for immuno-oncologySKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today reported full year financial results for the year ended December 31, 2017 and provided an update on corporate progress."Exicure is realizing the promise of our SNA technology through ongoing clinical advancements, including the launch of a ... 
Printer Friendly Version
01/31/18Exicure to Present at BIO CEO & Investor Conference, Immuno-Oncology 360° Summit and LEERINK Partners 7th Annual Global Healthcare Conference
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company update at the annual BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 1:45 pm EST at the New York Marriott Marquis in New York City. The company will also present at the Immuno-Oncology 360° Summit (IO360°... 
Printer Friendly Version
01/05/18Exicure, Inc. to Present at Biotech Showcase 2018
SKOKIE, Ill.--(BUSINESS WIRE)--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that the company is scheduled to present at the 10th Annual Biotech Showcase conference held January 8-10, 2018 in San Francisco.Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company overview on Tuesday, January 9th at 10:15 a.m. Pacific Time ... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet